55Biography
Manuel Beltrán Visiedo is currently a Post-Doctoral Associate with the Galluzzi Lab, where he investigates BCL2 as a therapeutic target to increase the immunostimulatory effects of radiation therapy in breast cancer. Prior to joining the Galluzzi Lab (2024), he was a Ph.D. student with the Anel and Marzo Lab in the Department of Biochemistry and Molecular and Cell Biology at the University of Zaragoza (Spain; 2018-2023), where he obtained his Ph.D. in Biochemistry and Molecular Biology (2023) after receiving his B.Sc. (2016) in Biotechnology and his M.Sc. (2017) in Biochemistry and Molecular Biology from the University of Zaragoza (Spain). Manuel has a long-standing interest in the role of cell death alterations in tumor sensitivity to targeted therapies and immunotherapy.
(Co)-first Authored Publications
- Catanzaro, E., Beltrán-Visiedo, M., Galluzzi, L. and Krysko, D. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol, 2025. IN PRESS.
- Beltrán-Visiedo, M., Balachandran, S. and Galluzzi, L. MRE11 mobilizes CGAS and drives ZBP1-dependent necroptosis. Cell Res, 2024. 34(7): p. 477-478.
- Beltrán-Visiedo, M., Serrano-Del Valle, A., Jiménez-Aldúan, N., et al. Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow. Methods Cell Biol, 2024. 189: p. 189-206.
Abstracts Selected for Poster Presentation
1. Beltrán-Visiedo, M., Soler-Agesta, R., Guilbaud, E., et al. MOMP-dependent cytotoxicity and immunogenicity of radiation therapy in breast cancer. AACR IO (American Association for Cancer Research) (February, 2025).
2. Beltrán-Visiedo, M., Soler-Agesta, R., Guilbaud, E., et al. Mitochondrial involvement in the cytotoxicity and immunogenicity of radiation therapy. SITC (Society of Immunotherapy of Cancer) (November, 2024).
My Bibliography Link
https://www.ncbi.nlm.nih.gov/myncbi/manuel.beltran-visiedo.1/bibliography/public/